Figure 2.
Timeline and effects of Coversin. (A) Timeline of events including GVHD and MAHA. (B) Effect of increasing concentrations of Coversin and eculizumab on CH50 in patient and normal control serum. (C) CH50 during treatment with alternate day and daily Coversin. (D) LDH levels (U/L) and reticulocyte count (103/mm3) during treatment with eculizumab and Coversin. Shaded areas in the boxes showing the duration of Coversin therapy indicate where daily therapy was given, and unshaded areas in the boxes indicate where alternate day therapy was given.
